1 Glauser, T. A. et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology54, 2237, doi:10.1212/WNL.54.12.2237 (2000).
2 Schachter, S. C. et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology52, 732-737, doi:10.1212/wnl.52.4.732 (1999).
3 Shorvon, S. Oxcarbazepine: a review. Seizure9, 75-79, doi:10.1053/seiz.2000.0391 (2000).
4 Schütz, H., Feldmann, K. F., Faigle, J. W., Kriemler, H. P. & Winkler, T. The metabolism of 14C-oxcarbazepine in man. Xenobiotica16, 769-778, doi:10.3109/00498258609043567 (1986).
5 Flesch, G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig24, 185-203, doi:10.2165/00044011-200424040-00001 (2004).
6 May, T. W., Korn-Merker, E. & Rambeck, B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet42, 1023-1042, doi:10.2165/00003088-200342120-00002 (2003).
7 Kim, D. W. et al. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy. Epilepsia53, e9-12, doi:10.1111/j.1528-1167.2011.03318.x (2012).
8 Trileptal (oxcarbazepine) [package insert]. East Hanover, NJ. Novartis Pharmaceutical Corp.;2000.
9 Glauser, T. A. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy21, 904-919, doi:10.1592/phco.21.11.904.34513 (2001).
10 Wang, Y. et al. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacologica Sinica35, 1342-1350, doi:10.1038/aps.2014.76 (2014).
11 Kim, Y. S. et al. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. Seizure23, 208-212, doi:10.1016/j.seizure.2013.11.015 (2014).
12 Moon, J. et al. HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption. Epilepsia57, 1879-1886, doi:10.1111/epi.13566 PMID - 27666425 (2016).
13 Sattler, A., Schaefer, M. & May, T. W. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy. Seizure31, 149-154, doi:https://doi.org/10.1016/j.seizure.2015.07.018 (2015).
14 Anderson, B. J. & Holford, N. H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol48, 303-332, doi:10.1146/annurev.pharmtox.48.113006.094708 (2008).
15 Anderson, B. J. & Holford, N. H. G. Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans. Drug Metabolism and Pharmacokinetics24, 25-36, doi:https://doi.org/10.2133/dmpk.24.25 (2009).
16 McLeay, S. C., Morrish, G. A., Kirkpatrick, C. M. & Green, B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet51, 319-330, doi:10.2165/11598930-000000000-00000 (2012).
17 Park, K. J. et al. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. Clin Neuropharmacol35, 40-44, doi:10.1097/WNF.0b013e31824150a5 (2012).
18 Peng, J., Zhang, H. N., Liu, Z. S., Xu, H. & Wang, Y. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. Int J Clin Pharmacol Ther52, 684-692, doi:10.5414/cp202078 (2014).
19 Antunes, N. J. et al. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. Eur J Pharm Sci109s, S116-s123, doi:10.1016/j.ejps.2017.05.034 (2017).
20 Rodrigues, C. et al. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. Br J Clin Pharmacol83, 2695-2708, doi:10.1111/bcp.13392 (2017).
21 Faison, S. et al. Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR(®)) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation. Clin Pharmacol12, 135-147, doi:10.2147/CPAA.S256972 (2020).